Digital interactions increasingly shape how we engage with brands, yet the ones that leave the strongest impression often do so by being almost invisible.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.